Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

COVID-19 vaccination for patients with epilepsy: A Chinese expert consensus.

  • 2023-10
  • Epilepsy & behavior : E&B 147
    • Xuewu Liu
    • Qun Wang
    • Liankun Ren
    • Xiqin Fang
    • Zhiyi He
    • Jing Ding
    • Kang Wang
    • Huiqin Xu
    • Hua Zhang
    • Yijun Song
    • Qiang Lu
    • Meizhen Sun
    • Xiong Han
    • Lili Cao
    • Weihong Lin
    • Xiaoyi Li
    • Qing Zhang
    • Yao Ding
    • Furong Wang
    • Tiancheng Wang
    • Jiwen Wang
    • Xiaorong Liu
    • Yuan Wu
    • Yangmei Chen
    • Zhanhui Feng
    • Shoulei Wang
    • Xiangqing Wang
    • Yuguang Guan
    • Xufang Xie
    • Huapin Huang
    • Ming Zhang
    • Xiaoshan Wang
    • Zhen Hong
    • Wen Jiang
    • Yanbing Han
    • Yulei Deng
    • Jiangming Zhao
    • Jianxiang Liao
    • Yu Wang
    • Yajun Lian

Study Design

Type
Review
Coronavirus disease-2019 (COVID-19) first emerged in late 2019 and has since spread worldwide. More than 600 million people have been diagnosed with COVID-19, and over 6 million have died. Vaccination against COVID-19 is one of the best ways to protect humans. Epilepsy is a common disease, and there are approximately 10 million patients with epilepsy (PWE) in China. However, China has listed "uncontrolled epilepsy" as a contraindication for COVID-19 vaccination, which makes many PWE reluctant to get COVID-19 vaccination, greatly affecting the health of these patients in the COVID-19 epidemic. However, recent clinical practice has shown that although a small percentage of PWE may experience an increased frequency of seizures after COVID-19 vaccination, the benefits of COVID-19 vaccination for PWE far outweigh the risks, suggesting that COVID-19 vaccination is safe and recommended for PWE. Nonetheless, vaccination strategies vary for different PWE, and this consensus provides specific recommendations for PWE to be vaccinated against COVID-19.

Research Insights

    Back to top